FOLH1 and prostate cancer: Our findings suggest PSMA PET/MRI could be used to guide biopsy in patients with suspicious prostate cancer, with similar accuracy and reliability in comparison with mpMRI regarding lesion localization, but with a more robust assessment of lesion aggressiveness by semiquantitative parameters.